

Available at www.sciencedirect.com

ScienceDirect

journal homepage: www.ejcancer.com

Effect of time to sentinel-node biopsy on the prognosis of cutaneous melanoma

Antonio Tejera-Vaquerizo ^{a,*,1}, Eduardo Nagore ^{b,1}, Susana Puig ^{c,1}, Caroline Robert ^d, Philippe Saiag ^e, Paula Martín-Cuevas ^a, Elena Gallego ^f, Enrique Herrera-Acosta ^a, José Aguilera ^a, Josep Malvehy ^c, Cristina Carrera ^c, Andrea Cavalcanti ^g, Ramón Rull ^h, Antonio Vilalta-Solsona ^c, Emilie Lannoy ⁱ, Celine Boutros ^d, Naima Benannoune ^d, Gorana Tomasic ^j, Philippe Aegerter ^k, Sergi Vidal-Sicart ^l, Josep Palou ^c, LLúcia Alos ^m, Celia Requena ^b, Víctor Traves ⁿ, Ángel Pla ^o, Isidro Bolumar ^p, Virtudes Soriano ^q, Carlos Guillén ^b, Enrique Herrera-Ceballos ^a

^a Servicio de Dermatología, Instituto de Biomedicina de Málaga (IBIMA), Hospital Universitario Virgen de la Victoria/Universidad de Málaga, Boulevard Louis Pasteur, 32, 29071 Málaga, Spain

^b Department of Dermatology, Instituto Valenciano de Oncología, cl Profesor Beltrán Báguena, 8, 46009 Valencia, Spain

^c Melanoma Unit, Servicio de Dermatología y Anatomía Patológica, Hospital Clínic, Universidad de Barcelona, Institut d'investigacions biomèdiques August Pi i Sunyer (IDIBAPS), Villarroel 170, 08036 Barcelona, Spain

^d Department of Dermatology, Gustave Roussy Cancer Campus, 114 rue Édouard-Vaillant, 94805 Villejuif Cedex, France

^e Service de dermatologie générale et oncologique, Hôpital Ambroise-Paré, Université de Versailles, Boulogne cedex, France

^f Servicio de Anatomía Patológica, Instituto de Biomedicina de Málaga (IBIMA), Hospital Universitario Virgen de la Victoria/Universidad de Málaga, Málaga, Boulevard Louis Pasteur, 32, 29071 Málaga, Spain

^g Department of Surgery, Gustave Roussy Cancer Campus, 114 rue Édouard-Vaillant, 94805 Villejuif Cedex, France

^h Departamento de Cirugía, Hospital Clínic, Universidad de Barcelona, Villarroel 170, 08036 Barcelona, Spain

ⁱ Biostatistics and Epidemiology Unit, Gustave Roussy Cancer Campus, 114 rue Édouard-Vaillant, 94805 Villejuif Cedex, France

^j Department of Pathology, Gustave Roussy Cancer Campus, 114 rue Édouard-Vaillant, 94805 Villejuif Cedex, France

^k Service de Biostatistique et Informatique Médicale, Hôpital Ambroise-Paré, Boulogne, France

^l Servicio de Medicina Nuclear, Hospital Clínic Barcelona, Universidad de Barcelona, Institut d'investigacions biomèdiques August Pi i Sunyer (IDIBAPS), Villarroel 170, 08036 Barcelona, Spain

^m Departamento de Anatomía Patológica, Universidad de Barcelona, Villarroel 170, 08036 Barcelona, Spain

ⁿ Departamento de Anatomía Patológica, Instituto Valenciano de Oncología, cl Profesor Beltrán Báguena, 8, 46009 Valencia, Spain

* Corresponding author at: Facultad de Medicina de Málaga, Boulevard Louis Pasteur, 32, 29071 Málaga, Spain. Tel.: +34 957644564.

E-mail addresses: antoniotejera@aedv.es (A. Tejera-Vaquerizo), eduardo_nagore@ono.com (E. Nagore), susipuig@gmail.com (S. Puig), caroline.robert@gustaveroussy.fr (C. Robert), philippe.saiag@uvsq.fr (P. Saiag), paulamcuevas@hotmail.com (P. Martín-Cuevas), elenag313@yahoo.es (E. Gallego), eherreraacosta@gmail.com (E. Herrera-Acosta), jaguilera@uma.es (José Aguilera), jmalvehy@gmail.com (J. Malvehy), criscarrer@yahoo.es (C. Carrera), andrea.cavalcanti@gustaveroussy.fr (A. Cavalcanti), rrull@clinic.ub.es (R. Rull), vilalta@cancerpiel.com (A. Vilalta-Solsona), emilie.lannoy@gustaveroussy.fr (E. Lannoy), celine.boutros@gustaveroussy.fr (C. Boutros), naima.benannoune@gustaveroussy.fr (N. Benannoune), gorana.tomasic@gustaveroussy.fr (G. Tomasic), philippe.aegerter@apr.aphp.fr (P. Aegerter), svidal@clinic.ub.es (S. Vidal-Sicart), peppalau@gmail.com (J. Palou), lalos@clinic.ub.es (LLúcia Alos), celiareq@hotmail.com (C. Requena), victortraves@telefonica.net (V. Traves), apmocholi@gmail.com (Á. Pla), ibolumar@yahoo.es (I. Bolumar), vsoriano-fivo@hotmail.com (V. Soriano), guillencar@gmail.com (Carlos Guillén), eherrera@uma.es (E. Herrera-Ceballos).

¹ These authors contributed equally to this study.

<http://dx.doi.org/10.1016/j.ejca.2015.05.023>

0959-8049/© 2015 Elsevier Ltd. All rights reserved.

^o Departamento de Otorrinolaringología, Instituto Valenciano de Oncología, cl Profesor Beltrán Báguena, 8, 46009 Valencia, Spain

^p Departamento de Cirugía, Instituto Valenciano de Oncología, cl Profesor Beltrán Báguena, 8, 46009 Valencia, Spain

^a Departamento de Oncología Médica, Instituto Valenciano de Oncología, cl Profesor Beltrán Báguena, 8, 46009 Valencia, Spain

Received 10 February 2015; received in revised form 26 April 2015; accepted 21 May 2015

KEYWORDS

Melanoma
Prognosis
Sentinel lymph node
Waiting list
Skin surgery

Abstract Introduction: In patients with primary cutaneous melanoma, there is generally a delay between excisional biopsy of the primary tumour and sentinel-node biopsy. The objective of this study is to analyse the prognostic implications of this delay.

Patients and method: This was an observational, retrospective, cohort study in four tertiary referral hospitals. A total of 1963 patients were included. The factor of interest was the interval between the date of the excisional biopsy of the primary melanoma and the date of the sentinel-node biopsy (delay time) in the prognosis. The primary outcome was melanoma-specific survival and disease-free survival.

Results: A delay time of 40 days or less (hazard ratio (HR), 1.7; confidence interval (CI), 1.2–2.5) increased Breslow thickness (Breslow ≥ 2 mm, HR, >3.7 ; CI, 1.4–10.7), ulceration (HR, 1.6; CI, 1.1–2.3), sentinel-node metastasis (HR, 2.9; CI, 1.9–4.2), and primary melanoma localised in the head or neck were independently associated with worse melanoma-specific survival (all $P < 0.03$). The stratified analysis showed that the effect of delay time was at the expense of the patients with a negative sentinel-node biopsy and without regression.

Conclusion: Early sentinel-node biopsy is associated with worse survival in patients with cutaneous melanoma.

© 2015 Elsevier Ltd. All rights reserved.

1. Introduction

Sentinel lymph node is a standard staging procedure in melanoma management. Although its relevance in overall survival has not been clearly demonstrated so far, its value to stratify melanoma patients into prognostic groups is unquestionable [1].

There is, usually a delay between excision of the primary tumour and performance of sentinel-node biopsy, attributable to multiple factors, including surgical scheduling, preoperative assessment and planning, and sometimes, limited health care resources. The influence of this delay in prognosis remains unclear to date. Three decades ago, Sim et al. [2] evaluated the therapeutic value of elective lymph node dissection and compared immediate lymphadenectomy versus delayed lymphadenectomy between 2 and 4 months bearing in mind the possible role of the regional lymph defensive system of the host against melanoma. They found no significant differences in survival but the arm of patients treated by immediate lymphadenectomy ($n = 54$) showed a slight tendency to metastasise before with a worse prognosis ($n = 55$). More recently, Parrett et al. evaluated the effect of time to sentinel-node biopsy on sentinel-node involvement, recurrence, and mortality, and found no significant differences in survival on comparing a delay time of less than 40 days with one of 40 days or more [3]. They did, however, detect a trend

towards higher melanoma-specific mortality in patients who underwent early sentinel-node biopsy (less than 40 days) and attributed this to a higher frequency of ulceration and thicker tumours in this group. They also admitted that their results were underpowered due to the relatively small number of patients evaluated ($n = 492$).

This delay time has not been sufficiently studied regarding the prognosis of these patients.

The objective of this study was to further evaluate in a large series of patients the effect on survival of the delay between excision of a primary melanoma and performance of sentinel-node biopsy.

2. Patients and methods

We performed a multi-institutional retrospective observational study in which we selected all cases of primary cutaneous melanoma registered in databases at four hospitals: Hospital Universitario ‘Virgen de la Victoria’ (HUVV) in Malaga, Spain; Instituto Valenciano de Oncología (IVO) in Valencia, Spain; Hospital Clínic Universitari de Barcelona (HCUB) in Barcelona, Spain; and Gustave-Roussy (GR) in Villejuif-Paris, France. It is noteworthy that all databases included patients’ data in a prospective way. Relevant ethical standards regarding the use of databases were applied in all cases.

Download English Version:

<https://daneshyari.com/en/article/8441902>

Download Persian Version:

<https://daneshyari.com/article/8441902>

[Daneshyari.com](https://daneshyari.com)